II-VI Incorporated Receives Optical Communications Industry Awards at ODC 2020
January 14 2021 - 04:30PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

II-VI Incorporated (Nasdaq: IIVI), a leading supplier of optoelectronic devices and micro-optics, today announced that it was twice recognized at a recent industry awards ceremony in China.
II-VI was ranked #3 in the category of “Top 10 competitiveness enterprises in the optical components and auxiliary equipment field of global market in 2020” and ranked #8 in the category of “Top 10 brand competitiveness enterprises in the optical communications field of China market in 2020” at the awards ceremony held during the 2020 (14th) Global & China Optical Communications Development and Competitiveness Forum (ODC 2020) in Beijing, China.

The II-VI Asia Regional Headquarters is located in Fuzhou, China. II-VI maintains a large manufacturing operations and product development presence in China in the cities of Fuzhou, Guangzhou, Shanghai, Shenzhen, Suzhou, and Wuxi.

About II-VI Incorporated

II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in communications, materials processing, aerospace & defense, semiconductor capital equipment, life sciences, consumer electronics, and automotive markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to support our customers. For more information, please visit us at www.ii-vi.com.

CONTACT: Mark Lourie
Vice President, Corporate Communications
corporate.communications@ii-vi.com
www.ii-vi.com/contact-us

https://www.covidx.eu/plx-pad#PLX-PAD2020-10-12

The real question: Is MESO worth 5x PSTI. Read the sticky.

The deception is great on both sides so if you really want the truth you will have to dig for it. There is a deeper spiritual battle going on behind the scenes. Major climate change will happen exactly as predicted almost 2000 years ago. If you are an honest skeptic and really want the Truth, this can help you on your journey... Skeptical? I hope so!

The article was fairly accurate but the author looks to be stuck on social distancing and does not want to be part of the big squeeze. Transfer from weak hands to strong hands continues and IMHO, the jack in the box music is getting close to stopping and then POP!!!

He fails to offer a reasonable evaluation of what the stock should be worth after their first approval. He also failed to mention that PSTI does not need to raise any funds until after they learn of the phase 3 trial results.

Why invest in PSTI & not one of the other competitors?

1) Market Cap opportunity. Valued at less than half the Market Cap of the nearest competitor means that $PSTI would have to double in stock price just to be at an equal market value with $ATHX and 5x the current stock price to be valued the same as $MESO, so all else being equal, the opportunity for investors is significant just to catch up with competitive market valuation. But all is not equal, as you will see.

2) Ability to Scale. This is why Pluristem was chosen by the EU as the only company to get a low cost 50 million Euro loan because they had already been ramping up for large scale production before this pandemic.

3) They own the IP and they continue to update and improve the process for greater efficiency. As if the current patented 3D bioreactor that can make 20,000 doses from one placenta was not enough, they have a new patent for a modular 3D bioreactor for even higher production.

4) They have their own manufacturing. This gives them full control over the process for consistency and will keep the costs lower than the competition. Their patented advanced process can be used for many other plant and animal cell cultures in the future when time and capitol permit. This process alone might be worth more than their current MarketCap.

5) Off the shelf product. The cells can be used on anyone without matching. They have the full cold storage chain process all set up even to the point of their patented thawing device that insures consistency with the optimal potency. They can transport their cells to any hospital in about 4 hours.

6) They use placenta cells from a young healthy C-section birth. It has yet to be proven, but some theorize that these cells have additional beneficial properties that are not found in cord blood or bone marrow MSC stem cells (Celularity also uses placenta cells).

7) Intramuscular injections delivery. This allows the PLX cells to give active therapeutic benefits much longer than intravenous and does not interfere with any other medications that may be administered IV.

8) Accelerated clinical environment. People want solutions that are safe and non-toxic and they want them now. I don't know if one of the governments will pickup the acute radiation PLX-18 or if NASA will continue funding the space atrophy studies but once we get our CLI phase III results and approval, off-label can do many things in this new paradigm.

Pluristem Therapeutics PSTI now has CASH, Institutional support & a major analyst (Jefferies). With today's markets, now is the time to already have your funding. Regardless of the stock price, they should be able to finish this year with at least one phase 3 study finished. PSTI should also have COVID phase II trials completed addressing the most critical and urgent need for COVID-19 SARS CoV-2 patients that are admitted into the ICU. To be fair, MESO is a few months ahead in the timeline for clinical trials but it is not always the first mouse that gets the cheese.

For those sleuths studying COVID stemcell treatments from others such as Mesoblast (MESO) , Miami Hospital (that also got compassionate use using similar approach with MSC stem cells), ATHX and Celularity, then collectively statics start looking impressive for MSC stem cells for treating COVID19 with severe symptoms even for such a small scale sample. The amazing fact is that compassionate use is used only in the most dire ICU cases. Look at improvement in organ function as another benefit. When someone is not conscious, how can you claim any placebo effect? The future use for pneumonia and ARDS is a huge new bonus market potential. Competitors are spreading a lot of misinformation in “articles”, so look closely into the manufacturing capabilities and strong IP with low cost of making 20 thousand doses from one placenta and the consistency of their whole process. Many do not know that years ago Pluristem had promising pre-clinical results treating ARDS but at the time had to put it on the back burner using their limited funds to further their current clinical trials.

Pluristem is the only really pure play as other top competitors either pay royalties or license fees, farm out manufacturing or split with partners. I do not think that vaccines will be the answer to the current situation as this virus mutates so quickly. How many people do you know who get the flu shot every year and still get the flu? Keeping people from dying is the best we can do and I believe PSTI can be one of the ways we do that and it can also work with other treatments as well.

Pluristem Therapeutics PSTI now has CASH, Institutional support & a major analyst (Jefferies). With today's markets, now is the time to already have your funding. Regardless of the stock price, they should be able to finish this year with at least one phase 3 study finished. PSTI should also have COVID phase II trials completed addressing the most critical and urgent need for COVID-19 SARS CoV-2 patients that are admitted into the ICU.

For those sleuths studying COVID stemcell treatments from others such as Mesoblast (MESO) , Miami Hospital (that also got compassionate use using similar approach with MSC stem cells), ATHX and Celularity, then collectively statics start looking impressive for MSC stem cells for treating COVID19 with severe symptoms even for such a small scale sample. The amazing fact is that compassionate use is used only in the most dire ICU cases. Look at improvement in organ function as another benefit. When someone is not conscious, how can you claim any placebo effect? The future use for pneumonia and ARDS is a huge new bonus market potential. Competitors are spreading a lot of misinformation in “articles”, so look closely into the manufacturing capabilities and strong IP with low cost of making 20 thousand doses from one placenta and the consistency of their whole process. Many do not know that years ago Pluristem had promising pre-clinical results treating ARDS but at the time had to put it on the back burner using their limited funds to further their current clinical trials.

Pluristem is the only really pure play as other top competitors either pay royalties or license fees, farm out manufacturing or split with partners. I do not think that vaccines will be the answer to the current situation as this virus mutates so quickly. How many people do you know who get the flu shot every year and still get the flu? Keeping people from dying is the best we can do and I believe PSTI can be one of the ways we do that and it can also work with other treatments as well.

Why invest in PSTI & not one of the other competitors?

1) Market Cap opportunity. Valued at less than half the Market Cap of the nearest competitor means that $PSTI would have to double in stock price just to be at an equal market value with $ATHX and 5x the current stock price to be valued the same as $MESO, so the opportunity for investors is significant just to catch up with competitive market valuation.

2) Ability to Scale. This is why Pluristem was chosen by the EU as the only company to get a low cost 50 million Euro loan because they had already been ramping up for large scale production before this pandemic.

3) They own the IP and they continue to update and improve the process for greater efficiency. As if the current patented 3D bioreactor that can make 20,000 doses from one placenta was not enough, they have a new patent for a modular 3D bioreactor for even higher production.

4) They have their own manufacturing. This gives them full control over the process for consistency and will keep the costs lower than the competition. Their patented advanced process can be used for many other plant and animal cell cultures in the future when time and capitol permit. This process alone might be worth more than their current MarketCap.

5) Off the shelf product. The cells can be used on anyone without matching. They have the full cold storage chain process all set up even to the point of their patented thawing device that insures consistency with the optimal potency. They can transport their cells to any hospital in about 4 hours.

6) They use placenta cells from a young healthy C-section birth. It has yet to be proven, but some theorize that these cells have additional beneficial properties that are not found in cord blood or bone marrow MSC stem cells (Celularity also uses placenta cells).

7) Intramuscular injections delivery. This allows the PLX cells to give active therapeutic benefits much longer than intravenous and does not interfere with any other medications that may be administered IV.

8) Accelerated clinical environment. People want solutions that are safe and non-toxic and they want them now. I don't know if one of the governments will pickup the acute radiation PLX-18 or if NASA will continue funding the space atrophy studies but once we get our CLI phase III results and approval, off-label can do many things in this new paradigm.

It is the reason they stated for the share increase (in case of a takeover bid). Musical chairs for shares? When the music stops, someone is going to be hurting, looking for shares to cover.

If you care about the truth, this is a start.

Look for the facts not the sound bites. Are you sure you know the truth about what actually happened? Can you name one employee on the "pandemic team" that was layed off? What was the "pandemic team" involved with before the "reorganization"? Trump did try to reduce the staff but it did not actually happen. The "expert" advisors that distill and filter all the information that any President would rely on had been in place for many administrations. No President is an expert in every field and must rely on the advisors to filter out what is important. The real question is why did the advisors trust and rely on the WHO and fail to do there own research?

It is not called a "Double Blind" study for nothing !!!

Hey, you got something right! Although "soon" is quite relative when your talking about 1990 years.

https://www.zerohedge.com/geopolitical/new-pneumonia-much-higher-fatality-rate-covid-discovered-kazakhstan-china-says

We lost our moderator & I guess the stickies went with them?

I'm guessing, but the birth process can be quite stressful (or so I'm told) and avoiding the placenta going through the birth canal seems wise for Pluristem's purposes.

Pluristem Therapeutics PSTI now has something that it has never had before, CASH. With today's markets, now is the time to already have your funding. Regardless of the stock price, they should be able to finish this year with at least one phase 3 study finished. PSTI should also have COVID phase II trials completed addressing the most critical and urgent need for Coronavirus COVID-19 SARS CoV-2 patients that are admitted into the ICU.

For those sleuths studying COVID stemcell treatments from others such as Mesoblast (MESO) , Miami Hospital (that also got compassionate use using similar approach with MSC stem cells), ATHX and Celularity, then collectively statics start looking impressive for MSC stem cells for treating COVID19 with severe symptoms even for such a small scale sample. The amazing fact is that compassionate use is used only in the most dire ICU cases. Look at improvement in organ function as another benefit. When someone is not conscious, how can you claim any placebo effect? The future use for pneumonia and ARDS is a huge new bonus market potential. Competitors are spreading a lot of misinformation in “articles”, so look closely into the manufacturing capabilities and strong IP with low cost of making 20 thousand doses from one placenta. Many do not know that years ago Pluristem had promising pre-clinical results treating ARDS but at the time had to put it on the back burner using their limited funds to further their current clinical trials.

Pluristem is the only really pure play as other top competitors either pay royalties or license fees, farm out manufacturing or split with partners. I do not think that vaccines will be the answer to the current situation as this virus mutates so quickly. How many people do you know who get the flu shot every year and still get the flu? Keeping people from dying is the best we can do and I believe PSTI can be one of the ways we do that and it can also work with other treatments as well.

Why invest in PSTI & not one of the other competitors?

1) Market Cap opportunity. Valued at less than half the Market Cap of the nearest competitor means that $PSTI would have to double in stock price just to be at an equal market value with $ATHX and 5x the current stock price to be valued the same as $MESO, so the opportunity for investors is significant just to catch up with competitive market valuation.

2) Ability to Scale. This is why Pluristem was chosen by the EU as the only company to get a low cost 50 million Euro loan because they had already been ramping up for large scale production before this pandemic.

3) They own the IP and they continue to update and improve the process for greater efficiency. As if the current patented 3D bioreactor that can make 20,000 doses from one placenta was not enough, they have a new patent for a modular 3D bioreactor for even higher production.

4) They have their own manufacturing. This gives them full control over the process for consistency and will keep the costs lower than the competition. Their patented advanced process can be used for many other plant and animal cell cultures in the future when time and capitol permit. This process alone might be worth more than their current MarketCap.

5) Off the shelf product. The cells can be used on anyone without matching. They have the full cold storage chain process all set up even to the point of their patented thawing device that insures consistency with the optimal potency. They can transport their cells to any hospital in about 4 hours.

6) They use placenta cells from a young healthy C-section birth. It has yet to be proven, but some theorize that these cells have additional beneficial properties that are not found in cord blood or bone marrow MSC stem cells (Celularity also uses placenta cells).

7) Intramuscular injections delivery. This allows the PLX cells to give active therapeutic benefits much longer than intravenous and does not interfere with any other medications that may be administered IV.

8) Accelerated clinical environment. People want solutions that are safe and non-toxic and they want them now. I don't know if one of the governments will pickup the acute radiation PLX-18 or if NASA will continue funding the space atrophy studies but once we get our CLI phase III results, off-label can do many things in this new paradigm.

That is how shorts try to cover while trying to make the chart look bad.

ARDS is the biggest threat and PSTI is the best solution.
https://www.zerohedge.com/health/thousands-dutch-covid-19-survivors-left-permanent-lung-damage-according-top-pulmonologist

Be prepared. They already stated that COVID was going to delay CLI because hospital were not doing anything but COVID and emergencies.

They need to have a crossover option. If the placebo patient does not show any improvement after 5 days, then cross them over for compassionate use. This would greatly help enroll the study.

They need to have BARDA stock pile and use the SR72 to deliver anywhere in the world in one hour. LOL

"Dr. De La Rosa and his colleagues had already been conducting a study injecting patients suffering from arterial ulcers—preventing circulation to the lower parts of their bodies, leading to possible amputation—with Israeli company Pluristem Therapeutics’ human placental cells. “It had very good success,” he said.

As the Times of Israel explained, the treatment “uses placentas to grow smart cells, and programs them to secrete therapeutic proteins in the bodies of sick people.”

https://www.zerohedge.com/geopolitical/chinas-newest-covid-19-outbreak-shows-virus-may-be-mutating

https://galusaustralis.com/2020/05/650950/global-critical-limb-ischemia-drug-market-2020-competitive-analysis-reneuron-group-plc-hemostemix-inc-u-s-stem-cell-inc/

Lots of things you "hear" can be twisted. As Chuck Missler used to say, "if you torture the data long enough, it will confess to anything". https://www.slashgear.com/viral-nicotine-coronavirus-protection-report-spreads-dangerous-misinformation-30618854/

"Mangalmurti says she has been “shocked by the fact that we don’t have a huge number of asthmatics” or patients with other respiratory diseases in HUP’s ICU. “It’s very striking to us that risk factors seem to be vascular: diabetes, obesity, age, hypertension.”

https://www.sciencemag.org/news/2020/04/how-does-coronavirus-kill-clinicians-trace-ferocious-rampage-through-body-brain-toes

Nice find !!!

I have revised and updated my sticky. Could you please replace.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155646018

Thanks.

Pluristem Therapeutics PSTI now has something that it has never had before CASH. With today's markets, now is the time to already have your funding. Regardless of the stock price, they should be able to finish this year with at least one phase 3 study finished (maybe two). PSTI should also have COVID phase II trials completed addressing the most critical and urgent need for Coronavirus COVID-19 SARS CoV-2 patients that are admitted into the ICU.

For those sleuths studying COVID stemcell treatments from others such as Mesoblast (MESO) , Miami Hospital (that also got compassionate use using similar approach with MSC stem cells), ATHX and Celularity, then collectively statics start looking impressive for MSC stem cells for treating COVID19 with severe symptoms even for such a small scale sample. The amazing fact is that compassionate use is used only in the most dire ICU cases. Look at improvement in organ function as another benefit. When someone is not conscious, how can you claim any placebo effect? The future use for pneumonia and ARDS is a huge new bonus market potential. Competitors are spreading a lot of misinformation in “articles”, so look closely into the manufacturing capabilities and strong IP with low cost of making 20 thousand doses from one placenta. Many do not know that years ago Pluristem had promising pre-clinical results treating ARDS but at the time had to put it on the back burner using their limited funds to further their current clinical trials.

Pluristem is the only really pure play as other top competitors either pay royalties or license fees, farm out manufacturing or split with partners. I do not think that vaccines will be the answer to the current situation as this virus mutates so quickly. How many people do you know who get the flu shot every year and still get the flu? Keeping people from dying is the best we can do and I believe PSTI can be one of the ways we do that and it can also work with other treatments as well so that we can get past the pandemic lockdowns.

Why invest in PSTI and not one of the other competitors?

1) Market Cap. Valued at less than half the Market Cap of the nearest competitor means that $PSTI would have to double in stock price just to be at an equal market value with $ATHX and 5x the current stock price to be valued the same as $MESO, so the opportunity for investors is significant just to catch up with competitive market valuation.

2) Ability to Scale. This is why Pluristem was chosen by the EU as the only company to get a low cost 50 million Euro loan because they had already been ramping up for large scale production before this pandemic.

3) They own the IP and they continue to update and improve the process for greater efficiency. As if the current patented 3D bioreactor that can make 20,000 doses from one placenta was not enough, they have a new patent for a modular 3D bioreactor for even higher production.

4) They have their own manufacturing. This gives them full control over the process for consistency and will keep the costs lower than the competition. Their patented advanced process can be used for many other plant and animal cell cultures in the future when time and capitol permit. This process alone might be worth more than their current MarketCap.

5) Off the shelf product. The cells can be used on anyone without matching. They have the full cold storage chain process all set up even to the point of their patented thawing device that insures consistency with the optimal potency. They can transport their cells to any hospital in about 4 hours.

6) They use placenta cells from a young healthy C-section birth. It has yet to be proven, but some theorize that these cells have additional beneficial properties that are not found in cord blood or bone marrow MSC stem cells (Celularity also uses placenta cells).

7) Accelerated clinical environment. People want solutions that are safe and non-toxic and they want them now. I don't know if one of the governments will pickup the acute radiation PLX-18 or if NASA will continue funding the space atrophy studies but once we get our CLI phase III results, off-label can do many things in this new paradigm.

"Jefferies anticipates the range for the Russell 2000 between $4.1 billion to about $60 million"

https://finance.yahoo.com/news/explainer-russell-index-reconstitution-coming-162520211.html

https://sciencebusiness.net/covid-19/regenerating-bodys-healing-mechanisms-covid-19-patients

$PSTI $MESO Vaccines - not the answer... https://www.zerohedge.com/health/coronavirus-mutates-now-dominant-more-contagious-form-doctors-ponder-east-coast-vs-west

MSC the best hope for advanced COVID-19 cases. MESO is 5x the market cap. I choose to invest into PSTI. They have CASH from the EU & many advantages for scaling, cost of treatment & cold storage supply.

https://www.eib.org/en/stories/placenta-cell-therapy-cure-covid-19

"The three-dimensional reactor mimics the conditions of the human body, enabling cells to grow. The technology allows Pluristem to produce a large number of treatments – up to 20 000 – from one placenta. Mass production is a key advantage during a global pandemic.

Growing the cells is one thing, but how do you get a treatment to the patient?

The company has created a cold chain distribution process to ensure that cells aren’t damaged or destroyed. That distribution method gives the cells a shelf life, meaning they can be stored for future treatments."

https://medium.com/illumination/horizontal-transfer-of-mitochondria-an-unknown-superpower-bbbc03aace32

This is a competitor to $PSTI (at least as far as COVID is concerned) also using Placenta MSC cells. https://www.tonyrobbins.com/podcasts/breakthroughs-in-immunity/

Pluristem PSTI COVID media list - https://www.pluristem.com/from-the-media/

Are we done? I don't think so

https://thefly.com/landingPageNews.php?id=3085300&headline=PSTI-Pluristem-options-imply--move-in-share-price-postearnings

"The company is one of several biotech firms aiming to use
mesenchymal stem cells as a potential COVID-19 treatment.
Cleveland-based Athersys, which is working on stem cell therapies
for strokes, heart disease and other conditions, is also expected to
begin clinical trials soon. Haifa, Israel-based Pluristem, which is
developing stem cell treatments as well, secured 50 million Euro
(about $55.4 million) in financing this week from the European
Investment Bank to support its COVID-19 trials."